Sudoxicam (4-Hydroxy-2-methyl-N-2-thiazolyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) is a reversible antagonist of COX with anti-inflammatory, anti-edema, and antipyretic properties.

Sudoxicam binds covalently to NADPH-dependent human liver microsomes. When glutathione (GSH) was added to the microsomal incubation, about half of the covalent binding of sudoxicam was blocked by glutathione[1].

Sudoxicam (0.1 mg/kg, p.o) significantly inhibits edema formation. In rats, Sudoxicam (1, 3.3 and 10 mg/kg; orally) effectively reduces plasma inflammation units, decreases the inflamed hind-paws swelling and restores toward normal the daily gain in body weight. Sudoxicam (3.3 mg/kg, i.p.) counteracts the pyrexia induced by the intraperitoneal injection of typhoid/paratyphoid vaccine and maintains body temperature. In the guinea pig, Sudoxicam inhibits the erythema caused by ultraviolet irradiation. The plasma half-life of Sudoxicam is 8, 13 and hours for monkey, rat and dog[2].